Hangzhou Tigermed Consulting Co., Ltd. Class A · SZSE:300347
Hangzhou Tigermed Consulting Co., Ltd. Class A — H1 2022 Earnings Presentation
31 slides from Hangzhou Tigermed Consulting Co., Ltd. Class A's earnings presentation, August 2022
Slide 1: 2022 Interim Results
2022 Interim Results Hangzhou Tigermed Consulting Co., Ltd. 300347.SZ / 3347.HK August 2022 www.tigermedgrp.com
Slide 2: Disclaimer
Disclaimer This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2022 interim results announcement and other relevant announcements published on the websites of the Shenzhen Stock Exchange (
Slide 3: Results Overview
01 Results Overview
Slide 4: 1H2022 Key Financials
1H2022 Key Financials Adjusted Net Profit Attributable to the Owners Revenue Gross Profit and Margin of the Company and Margin(1) (RMB mm) (RMB mm) (RMB mm) 47.0% 39.5% 33.7% 24.4% 3,594.2 +74.8% 1,422.1 1,418.3 2,056.4 876.5 +46.7% +39.0% 966.9 692.1 +26.6% 1,022.8 2,172.1 1,033.6 +110.1% 1H2021 1H
Slide 5: Revenue Breakdown by China and Overseas Markets
Revenue Breakdown by China and Overseas Markets China Revenue Overseas Revenue Revenue Breakdown by Region (RMB mm) (RMB mm) 46% 1H2021 54% 1,913.4 China Overseas 1,680.8 +102.3% +51.3% 1,110.8 945.6 47% 1H2022 53% 1H2021 1H2022 1H2021 1H2022 China Overseas 5
Slide 6: Cost of Services
Cost of Services Cost of Services Breakdown by Nature and as % of Revenue (RMB mm) 53.0% 60.5% 2,175.9 5.2% +99.7% 28.9% 1,089.5 7.7% 15.8% 26.4% 29.5% 1H2021 1H2022 Direct labor costs Direct project-related costs Overhead costs 6
Slide 7: Operating Expenses
Operating Expenses Selling and Marketing Expenses Administrative Expenses and R&D Expenses and as Share-based Compensation and as % of Revenue as % of Revenue % of Revenue and as % of Revenue (RMB mm) (RMB mm) (RMB mm) (RMB mm) 3.2% 2.2% 12.0% 8.9% 4.5% 3.1% 2.2% 0.7% 321.4 +30.3% 246.7 80.0 110.5 +
Slide 8: Business Updates: Clinical Trial Solutions
02 Business Updates Clinical Trial Solutions
Slide 9: Clinical Trial Solutions ("CTS")
Clinical Trial Solutions (“CTS”) Segment Revenue Segment Gross Profit and Margin (RMB mm) (RMB mm) 50.6% 36.9% 2,172.1 +110.1% 800.7 1,033.6 +53.0% 523.5 1H2021 1H2022 1H2021 1H2022 9
Slide 10: CTS Key Business Updates
CTS Key Business Updates Number of Ongoing Drug Clinical Number of Ongoing Drug Clinical Research Projects by Phase(1) Research Projects by Region(1) 607 607 600 600 567 52 567 58 45 37 50 491 37 491 500 500 37 29 149 149 132 39 148 111 400 400 137 117 300 300 106 85 200 200 385 400 351 252 231 100
Slide 11: CTS Key Business Updates (Cont'd)
CTS Key Business Updates (Cont’d) Overseas Clinical Operation Business Updates Number of Ongoing Overseas Drug Clinical Research(1) ⚫ 149 ongoing single region overseas clinical trials as of June 30, 2022, primarily in South Korea, 207 Australia and the United States 200 ⚫ 58 ongoing MRCTs as of Jun
Slide 12: CTS Key Business Updates (Cont'd)
CTS Key Business Updates (Cont’d) Industry Leadership in the Clinical Service Market Tigermed team enabled successful approvals of 4 China Class I innovative drugs in 1H 2022 Tigermed has the largest market share of Tigermed is the only China-based clinical 12.5% in China’s clinical outsourcing mark
Slide 13: CTS Key Business Updates (Cont'd)
CTS Key Business Updates (Cont’d) Positioned to further enhance decentralized trial management and risk-based monitoring capabilities Centralized Decentralized Clinical Trials Clinical Trials ⚫ Enhanced patient ⚫ Tailinyan (泰临研) platform offers multi-scenario solutions to patients, experience sponso
Slide 14: CTS Key Business Updates (Cont'd)
CTS Key Business Updates (Cont’d) Medical Device Clinical Research ⚫ Had 403 ongoing medical device projects(1) as of June 30, 2022 ⚫ Our medical device business ranked 2nd in China’s medical device outsourcing market with a 7.1% market share, and ranked 1st in China’s medical device clinical resear
Slide 15: CTS Key Business Updates (Cont'd)
CTS Key Business Updates (Cont’d) Pharmacovigilance (“PV”) and Real World Studies ⚫ Added 177 new PV projects in 1H2022 ⚫ Size of Tigermed PV team reached 128 as of June 30, 2022 ⚫ Formally launched our in-house developed eCPM(1) system in 1H2022, a patient-centric real world study management platfo
Slide 16: Business Updates: Clinical-related and Lab Services
03 Business Updates Clinical-related and Lab Services
Slide 17: Clinical-related and Lab Services ("CRLS")
Clinical-related and Lab Services (“CRLS”) Revenue Gross Profit and Margin (RMB mm) (RMB mm) 43.4% 43.4% 1,422.1 617.6 +39.0% 1,022.8 +39.3% 443.4 1H2021 1H2022 1H2021 1H2022 17
Slide 18: CRLS Key Business Updates
CRLS Key Business Updates Project Status for Key CRLS Services Data Management and Statistical Analysis Site Management Laboratory Services Completed Conducted 260 by team based overseas 1,469 2,872 2,664 Conducted Completed Completed 526 1,994 by team based in China 1,512 158 157 203 105 148 122 20
Slide 19: CRLS Key Business Updates (Cont'd)
CRLS Key Business Updates (Cont’d) Data Management & Statistical Analysis (“DMSA”) ⚫ DMSA team had 786 ongoing projects as of June 30, 2022, of which 526 projects were being conducted by We are the largest DMSA service provider in China with our team based in China and 260 projects by team based ove
Slide 20: CRLS Key Business Updates (Cont'd)
CRLS Key Business Updates (Cont’d) Laboratory Services ⚫ Expanded capacities in pharmacological safety assessment and toxicology services through the acquisition of Experimur (US), and further expanded our bioanalytical, biologics bioassay, and biomarker services through new 25,000 sq. ft. facility
Slide 21: Other Updates
O04 Other Updates
Slide 22: Updates of Investment Activities
Updates of Investment Activities Realized Investment Gain and Fair Value Gain(1) ⚫ Portfolio included 146 companies in the (RMB mm) 906.1 healthcare industry and 57 investment funds as of June 30, 2022 ⚫ RMB 9,713.3 mm balance as of June 30, 2022 ⚫ Invested RMB 340.8 mm in unlisted equities; and RMB
Slide 23: Employee Base
Employee Base Total employees decreased by 0.3% to 8,299 as of June 30, 2022 from 8,326 as of December 31, 2021 Employees Mix by Function(1) Employees Mix by Geography(1) Management and administration Overseas and China Hong Kong, Macau, Taiwan Marketing and business 463 1,151 development 6% 367 4%
Slide 24: Commitment to Sustainability
Commitment to Sustainability AAA in 2022 CNI ESG Ratings by Shenzhen Stock Exchange ⚫ In July 2022, Shenzhen Stock Exchange (“SZSE”) officially launched CNI ESG Ratings Methodology and released ESG indices and ESG leading indices of SZSE’s core indices (Shenzhen Component Index, ChiNext Index, Shenz
Slide 25: Enhanced Corporate Branding in 1H2022
Enhanced Corporate Branding in 1H2022 Mission Vision Advance human health through To be recognized as the leading delivery excellence global CRO Values Brand Identity Honesty, Accountability Passion for Innovation Respect, Partnership Global Excellence, China Expertise 25
Slide 26: Appendix
05 Appendix
Slide 27: Global and China Pharmaceutical R&D Service Market
Global and China Pharmaceutical R&D Service Market By R&D Stage, 2017-2026E Global CRO Market Size(1) China CRO Market Size(2) CAGR CAGR Time Period Time Period Discovery Preclinical Clinical Overall Discovery Preclinical Clinical Overall 2017-2021 10.4% 8.3% 9.7% 9.6% 2017-2021 37.5% 15.6% 20.1% 22
Slide 28: Consolidated Statement of Profit or Loss
Consolidated Statement of Profit or Loss Period ended June 30, (RMB 000s) 2021 2022 Revenue 2,056,375 3,594,209 Cost of services (1,089,456) (2,175,881) Gross profit 966,919 1,418,328 Other income 147,419 128,757 Other gains and losses, net 1,007,221 468,609 Impairment losses (10,252) (28,411) Selli
Slide 29: Consolidated Statement of Financial Position
Consolidated Statement of Financial Position (RMB 000s) As of December 31, 2021 As of June 30, 2022 NON-CURRENT ASSETS 12,891,285 14,993,243 Property, plant and equipment 701,857 824,671 Intangible assets 234,090 271,738 Goodwill 1,778,948 2,347,881 Right-of-use assets 473,262 477,068 Interests in a
Slide 30: Consolidated Statement of Financial Position (Cont'd)
Consolidated Statement of Financial Position (Cont’d) (RMB 000s) As of December 31, 2021 As of June 30, 2022 CURRENT LIABILITIES 2,412,716 3,434,473 Trade and other payables 879,962 632,059 Contract liabilities 789,509 819,623 Borrowings 492,320 1,761,905 Income tax payables 176,410 135,102 Lease li
Slide 31: 300347.SZ / 3347.HK
300347.SZ / 3347.HK Hangzhou Tigermed Consulting Co., Ltd. www.tigermedgrp.com
Hangzhou Tigermed Consulting — H1 2022 Earnings Presentation on 6ix